{"filing":{"accession_number":"0001628280-26-044263","cik":"0002036042","ticker":"SION","company_name":"Sionna Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"sion-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026044263/sion-20260617.htm"},"events":[{"id":11810,"run_id":10388,"accession_number":"0001628280-26-044263","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from Sionna Therapeutics' Annual Meeting of Stockholders held on June 17, 2026. The filing reports the voting outcomes for two proposals: (1) election of four Class II directors (H. Edward Fleming, Jr., Marcella Kuhlman Ruddy, Peter A. Thompson, and Joanne Louise Viney), and (2) ratification of Deloitte \u0026 Touche LLP as independent auditor. All nominees were elected and the auditor appointment was ratified. This is a routine but material disclosure required under Item 5.07 of Form 8-K.","company_name":"Sionna Therapeutics, Inc.","ticker":"SION","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8492,"accession_number":"0001628280-26-044263","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Sionna Therapeutics' Annual Meeting of Stockholders held on June 17, 2026. The filing reports the voting outcomes for two proposals: (1) election of four Class II directors (H. Edward Fleming, Jr., Marcella Kuhlman Ruddy, Peter A. Thompson, and Joanne Louise Viney), and (2) ratification of Deloitte \u0026 Touche LLP as independent auditor. All nominees were elected and the auditor appointment was ratified. This is a routine but material disclosure required under Item 5.07 of Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:07:46.604949+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8492,"accession_number":"0001628280-26-044263","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Sionna Therapeutics' Annual Meeting of Stockholders held on June 17, 2026. The filing reports the voting outcomes for two proposals: (1) election of four Class II directors (H. Edward Fleming, Jr., Marcella Kuhlman Ruddy, Peter A. Thompson, and Joanne Louise Viney), and (2) ratification of Deloitte \u0026 Touche LLP as independent auditor. All nominees were elected and the auditor appointment was ratified. This is a routine but material disclosure required under Item 5.07 of Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:07:46.604949+00:00","company_name":"Sionna Therapeutics, Inc.","ticker":"SION","filing_date":"2026-06-18"}]}